Thursday, October 15, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 12, 2026

Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners

View original at finance.yahoo.com
Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners The US is pursuing new tariffs on nations with which it trades, pivoting after the Supreme Court struck down President Trump's most sweeping tariffs under the International Emergency Economic Powers Act (IEEPA)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Customs agency cannot comply with federal judge's order to automatically refund importers' tariff payments without their requesting the refunds

    60% confidence

  • US businesses and consumers have paid for tariffs, pushing up inflation

    60% confidence

  • Trump administration's tariff refund delay is theft in broad daylight

    60% confidence

  • Electronic refund process will be ready within 45 days

    60% confidence

  • 15% global tariff could begin sometime this week

    60% confidence

  • US economic growth was muted in February as tariffs increased costs for businesses, some of which passed along higher prices to consumers

    60% confidence

  • Importers would receive only one payment from Treasury Department, regardless of how many items or declarations they filed

    60% confidence

Data points we hold from this source

Donald Trump · tariff revenue decline1 USD
Donald Trump · planned global tariff rate15 percent
Donald Trump · current global tariff rate10 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Trump tariffs live updates: US explores new tariffs in investigation targeting trading partners — Source | Via News | Via News